This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

Compared to Estimates, Health Catalyst (HCAT) Q2 Earnings: A Look at Key Metrics

Health Catalyst (HCAT) reported $70.49 million in revenue for the quarter ended June 2026, representing a year-over-year decline of 12.7%. EPS of $0.04 for the same period compares to $0.04 a year ago.

The reported revenue represents a surprise of +2.33% over the Zacks Consensus Estimate of $68.88 million. With the consensus EPS estimate being $0.02, the EPS surprise was +100%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Health Catalyst performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Revenue- Professional services: $21.69 million versus the two-analyst average estimate of $19.09 million. The reported number represents a year-over-year change of -22.1%.
Revenue- Technology: $48.8 million versus the two-analyst average estimate of $50 million. The reported number represents a year-over-year change of -7.7%.
Adjusted Gross Profit- Professional Services: $4.86 million versus the two-analyst average estimate of $3.24 million.
Adjusted Gross Profit- Technology: $30.98 million compared to the $32.75 million average estimate based on two analysts.

View all Key Company Metrics for Health Catalyst here>>>

Shares of Health Catalyst have returned +8.6% over the past month versus the Zacks S&P 500 composite's +3.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

7 Best Stocks for the Next 30 Days

Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."

Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.

See them now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Health Catalyst, Inc. (HCAT): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research